Assessment of four monoclonal antibodies as serum markers in breast cancer.
Four monoclonal-antibody-defined serum markers (CA15-3, HMFG1, HMFG2 and NCRC-11) were examined in five groups of subjects: controls, benign breast disease and stage I/II, stage III and metastatic breast cancer. None of the markers were significantly elevated in primary breast cancer (i.e. stage I/II or stage III) compared with controls or patients with benign breast disease. These markers therefore have no role in screening or in the diagnosis of primary breast cancer. CA15-3, HMFG2 and NCRC-11 were significantly increased in the patients with metastatic breast cancer (P less than 0.001), indicating a potential use in the diagnosis of symptomatic metastases. In patients with metastases, sequential changes in CA15-3 correlated significantly with clinical response to therapy. Thus CA15-3 is a powerful marker of response and in combination with other markers, may provide an objective measurement of response to therapy in patients with advanced breast cancer.
Robertson
J F
JF
Unit of Surgery, Christie Hospital, Manchester, U.K.
Pearson
D
D
Price
M R
MR
Selby
C
C
Badley
R A
RA
Pearson
J
J
Blamey
R W
RW
Howell
A
A
D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal; D015295:Antigens, Tumor-Associated, Carbohydrate / Q000032:analysis; D014408:Biomarkers, Tumor / Q000097:blood*; D001943:Breast Neoplasms / Q000175:diagnosis* / Q000473:pathology / Q000556:secondary; D005260:Female; D006801:Humans; D008562:Membrane Glycoproteins / Q000097:blood; D008875:Middle Aged; D018396:Mucin-1; D009367:Neoplasm Staging
D000911:Antibodies, Monoclonal; D015295:Antigens, Tumor-Associated, Carbohydrate; D014408:Biomarkers, Tumor; D008562:Membrane Glycoproteins; D018396:Mucin-1